The Max Planck Research Group of Systems Immunology is a collaborative effort between the Julius Maximilian University of Würzburg (JMU) and the Max Planck Society (MPG) aimed at promoting excellent immunological research. Around 50 researchers from more than 20 countries are working together to understand the basis of a successful immune response against infectious agents, chronic inflammatory diseases, and tumors. Their ultimate goal is to develop new concepts and strategies for vaccines and immunotherapies.
To achieve this, the group is investigating the development and function of the immune system holistically at multiple levels. They are conducting high-resolution analyses of single molecules and cells, examining complex cellular networks within organs, and exploring systemic interactions in the body and with the environment. These research goals align well with the internationally visible research on infectious diseases and immunotherapies at the Würzburg Life Science Campus.
As of 1 July 2026, Martin Vaeth has been appointed to the newly established W2 Professorship of Immunometabolism at the Institute of Systems Immunology, Julius-Maximilians-Universität Würzburg.
Successful work: The Collaborative Research Centre "Cardio-immune Interfaces" at Würzburg University Medicine receives a further twelve million euros from the German Research Foundation.
The International Max Planck Research School for Immunobiology, Epigenetics and Metabolism (IMPRS-IEM) - a joint international PhD Programme of the Max Planck Institute of Immunobiology and Epigenetics and the University of Freiburg
